Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
By Matt I. Gross, S. Demo, J. Dennison, Lijing Chen, T. Chernov-Rogan, B. Goyal, J. Janes, Guy J. Laidig, E. Lewis, Jim Li and 10 more. Molecular Cancer Therapeutics, 2014
934 citations recorded by the source corpus.
Subfields: Biotechnology, Cancer Research, Oncology
View Paper: https://www.semanticscholar.org/paper/5ff6910124b4522bcd3bd32325c1151d158431a8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biotechnology
In Cancer Research
- Jason W. Locasale
- M. V. Vander Heiden
- C. V. Dang
- D. Y. Gui
- Alba Luengo
- B. Altman
- Zachary E. Stine
- A. Gimenez-Roqueplo
In Oncology
Citations in the corpus
- Comprehensive molecular characterization of pheochromocytoma and paraganglioma (2017, background): “For example, SDH-mutant tumors have high levels of glutamine, and glutaminase inhibitors (Gross et al., 2014) are currently being evaluated inNCT02071862.”
- MYC, Metabolism, and Cancer. (2015, background): “These studies provided the foundation for the development of a drug-candidate GLS inhibitor that is now undergoing phase I clinical studies in humans (215).”
- Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer (2016, methodology): “5 nmol/g of tissue, an amount similar to that reported previously (Figure 5B) (Gross et al., 2014).”
- Targeting Metabolism for Cancer Therapy (2017, background): “…glutaminase genes, GLS and GLS2, and targeting the enzymes encoded by these genes with chemical inhibitors has been found to decrease cancer cell proliferation in both in vitro and in vivo models (Gross et al., 2014; Jacque et al., 2015; Le et al., 2012; Xiang et al., 2015; Yuneva et al., 2012).”
- Glutamine Metabolism in Cancer: Understanding the Heterogeneity (2017, positive): “Matching these expression patterns, most luminal breast cancer cells can be cultured in glutamine-free media, whereas basal cells are highly sensitive to glutamine withdrawal and to inhibition of GLS, both in cell culture and when grown as xenograft tumors in vivo [10,17].”